Skip to content

prospective study on precise localization and puncture of prostate cancer based on artificial intelligence and puncture robot

Exploratory study on establishing an artificial intelligence image interpretation model for precise localization of prostate cancer via puncture robot

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112695
Enrollment
Unknown
Registered
2025-11-18
Start date
2023-08-31
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Robot-assisted puncture observation group:None

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Male patients diagnosed with "suspected prostate malignancy observation" due to elevated PSA >4ng/ml, suspicious nodules in the prostate detected by digital rectal examination, or suspicious lesions in the prostate found by imaging, who are scheduled to undergo prostate biopsy. 2.PSA<10ng/ml; 3. There are preoperative pelvic/prostate MRI images available for MRI modeling, with a PI-RADS score of 2 or above. 4. The subjects fully understand the benefits and risks of this trial, are willing to participate, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with severe immunosuppression, dementia, chronic depression or mental illness, as well as those with multiple cell sclerosis and Parkinson's disease. 2. Lack of data reports on the diseases involved in the research; 3. Patients who have received the following treatments within the last three months: colorectal surgery, hemorrhoidectomy, transurethral resection of the prostate; 4. Patients with a history of pelvic radiotherapy before the operation; 5. Preoperative imaging and other examination results suggest locally advanced, distant metastasis and other conditions that do not meet the indications for focal treatment of prostate cancer.

Design outcomes

Primary

MeasureTime frame
Puncture positive rate;

Countries

China

Contacts

Public ContactBangmin Han

Shanghai General Hospital

hanbm@163.com+86 189 3975 7031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026